Method for using nanodiamonds to detect nearby magnetic nanoparticles

Patent metadata

Field	Value
Publication number	US-9435791-B2
Application number	US-201414318220-A
Country	US
Kind code	B2
Filing date	Jun 27, 2014
Priority date	Jun 27, 2014
Publication date	Sep 6, 2016
Grant date	Sep 6, 2016

Abstract

An imaging agent for detecting analytes in an environment includes functionalized nanodiamonds and functionalized magnetic particles that can selectively interact with an analyte. Each functionalized nanodiamond contains at least one color center configured emit light in response to illumination. At least one property of the light emitted by the color centers is related to the proximity of the functionalized magnetic particles to the color centers. This property can be detected to determine that the functionalized nanodiamonds are proximate to the functionalized magnetic particles, to determine that the functionalized nanodiamonds and the functionalized magnetic particles are interacting with the analyte, or other applications. Devices and methods for detecting properties of the analyte by interacting with the functionalized nanodiamonds and functionalized magnetic particles are also provided.

First claim

What is claimed is:

1. An in vivo imaging agent, comprising:
a plurality of functionalized magnetic nanoparticles, wherein each of the functionalized magnetic nanoparticles is functionalized to selectively interact with an analyte in an environment; and
a plurality of functionalized nanodiamonds, wherein each of the functionalized nanodiamonds contains at least one color center and is functionalized to selectively interact with the analyte in the environment, and wherein the at least one color center is configured to emit light in response to illumination, wherein the emitted light has one or more properties relating to proximity between the at least one color center and individual functionalized magnetic nanoparticles of the plurality of functionalized magnetic nanoparticles.

2. The in vivo imaging agent of claim 1 , wherein the color centers comprise negatively-charged nitrogen vacancy centers.

3. The in vivo imaging agent of claim 1 , wherein the plurality of functionalized magnetic nanoparticles comprises magnetic nanoparticles comprising superparamagnetic iron oxide.

4. The in vivo imaging agent of claim 1 , wherein each of the functionalized magnetic nanoparticles comprises a ferromagnetic material, a paramagnetic material, or a superparamagnetic material.

5. The in vivo imaging agent of claim 1 , wherein each of the functionalized magnetic nanoparticles is functionalized with a receptor, protein, antibody, or nucleic acid sequence.

6. The in vivo imaging agent of claim 1 , wherein each of the functionalized nanodiamonds is functionalized with a receptor, protein, antibody, or nucleic acid sequence.

7. The in vivo imaging agent of claim 1 , wherein the functionalized magnetic nanoparticles and the functionalized nanodiamonds are functionalized to selectively bind to cancer cells.

8. The in vivo imaging agent of claim 1 , wherein the environment is a human body and the analyte is a cancer cell.

9. The in vivo imaging agent of claim 1 , wherein the emitted light has one or more properties relating to a magnetic field produced or affected by one or more proximate functionalized magnetic nanoparticles.

10. The in vivo imaging agent of claim 1 , wherein the at least one color center exhibits optical properties that are related to a magnetic field in an environment of the at least one color center.

11. The in vivo imaging agent of claim 10 , wherein the at least one color center has a plurality of spin states, and wherein occupancy of the spin states is affected by the magnetic field in the environment of the at least one color center.

12. The in vivo imaging agent of claim 11 , wherein the occupancy of the spin states affects the one or more properties of the emitted light.

13. The in vivo imaging agent of claim 1 , further comprising a fluorophore attached to each of the functionalized magnetic nanoparticles.

14. The in vivo imaging agent of claim 1 , further comprising a fluorophore attached to each of the functionalized nanodiamonds.

15. The in vivo imaging agent of claim 1 , wherein each of the functionalized magnetic nanoparticles is functionalized by covalent attachment of a bioreceptor, wherein the bioreceptor specifically binds with at least a portion of the analyte.

16. The in vivo imaging agent of claim 1 , wherein each of the functionalized nanodiamonds is functionalized by covalent attachment of a bioreceptor, wherein the bioreceptor specifically binds with at least a portion of the analyte.

17. The in vivo imaging agent of claim 1 , wherein the color centers are silicon vacancy centers.

18. The in vivo imaging agent of claim 1 , wherein each instance of the analyte has at least a first binding site and a second binding site, wherein each of the functionalized magnetic nanoparticles is functionalized to bind with the first binding site, and wherein each of the functionalized nanodiamonds is functionalized to bind with the second binding site.

19. The in vivo imaging agent of claim 18 , wherein binding of an instance of the analyte to both a functionalized magnetic nanoparticle via the first binding site and a functionalized nanodiamond via the second binding site is detectable by the one or more properties of the emitted light from the at least one color center of the functionalized nanodiamond based on proximity of the functionalized magnetic nanoparticle and the functionalized nanodiamond.

20. The in vivo imaging agent of claim 1 , wherein the one or more properties of the emitted light include amplitude, wavelength, degree of polarization, orientation of polarization, or location of the emitted light.

Assignees

• Verily Life Sciences Llc
• Verily Life Sciences Llc

Inventors

• Acosta Victor Marcel
• Bajaj Vikram Singh
• Thompson Jason Donald
• Peeters Eric

Classifications

• G01N33/544

  the carrier being organic · CPC title

• A61B5/1455 Primary

  using optical sensors, e.g. spectral photometrical oximeters · CPC title

• A61K49/0002

  General or multifunctional contrast agents, e.g. chelated agents · CPC title

• G01N33/5091 Primary

  for testing the pathological state of an organism · CPC title

• A61K49/001

  Preparation for luminescence or biological staining · CPC title